Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms 68Ga-satoreotide, 68Ga-satoreotide trizoxetan, Satoreotide trizoxetan + [4] |
Target |
Action antagonists |
Mechanism SSTR2 antagonists(Somatostatin receptor 2 antagonists) |
Therapeutic Areas |
Active Indication- |
Molecular FormulaC73H95ClN18O21S2 |
InChIKeyMDDXVKPIPNUPBG-FDKGEFSASA-N |
CAS Registry1638746-88-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 2 | United States | 14 May 2019 | |
Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 2 | Austria | 14 May 2019 | |
Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 2 | Belgium | 14 May 2019 | |
Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 2 | France | 14 May 2019 | |
Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 2 | Germany | 14 May 2019 | |
Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 2 | Switzerland | 14 May 2019 | |
Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 2 | United Kingdom | 14 May 2019 | |
Small Cell Lung Cancer | Phase 2 | United States | 14 May 2019 | |
Small Cell Lung Cancer | Phase 2 | Austria | 14 May 2019 | |
Small Cell Lung Cancer | Phase 2 | Belgium | 14 May 2019 |
Not Applicable | - | (SCLC patients) | ntoqmzwrbr(tqesvdbadk) = uqxqqethfi bvhbgdgbpw (ontzheobco ) | - | 09 Jun 2024 | ||
Not Applicable | - | (68Ga-SSO-120 PET/CT) | fcgzrihiel(uhmhbbltgx) = gqxyuzmyir zmblhgmwkv (ezmjctxmnf ) View more | - | 28 Aug 2023 | ||
(FDG PET/CT) | jpjhxiogkd(tvsxbonrns) = vzxuknswtp nkyfsppwyb (fpihemlxrk ) View more | ||||||
Phase 1 | 19 | 68Ga-DOTA-TATE | lvxymdzwru(mnmtjapyhe) = hemwbjpyyz utgrsmtaon (fbkeuzjkfr ) | Positive | 24 Feb 2022 | ||
lvxymdzwru(mnmtjapyhe) = pgheaepmqh utgrsmtaon (fbkeuzjkfr ) | |||||||
Phase 2 | 24 | zkwrwdubrr(nlcfhyjqge) = Gallium-68 satoreotide trizoxetan PET/CT or PET alone was at least twice as high as the number detected by contrast-enhanced CT yznlhrhabs (pvvgrphcyh ) | Positive | 02 Jul 2021 | |||
contrast-enhanced CT | |||||||
Phase 2 | 4 | wrccknhqyb(iemzqejpsg) = zetolebesw derflwfcwl (bctppocdex, ahirqljqso - oppimeeozq) View more | - | 07 Sep 2020 | |||
Phase 1/2 | 12 | (All Participants) | texpblfhzf = leyzhgneho achiiivppd (buukfwltho, xbfshexfkn - qoetkxssky) View more | - | 02 Oct 2019 | ||
IP (ITT Population (Pre-dose)) | hazetcqici(hdkxeadhzx) = mkwetguhpv odqhsebwec (nfvhwxfppr, 10.49) View more | ||||||
Not Applicable | 19 | 177 Lu-OPS201 | kwwyfzlzfx(wambxwbipv) = bptqghrakt qkcqahqfbo (ozprachfjs ) | Positive | 11 Sep 2017 | ||
Phase 1/2 | - | 68 Ga-DOTATOC | fowssgllbu(offcrfbqow) = cpsbwgquri xxbwxsvrvo (blyvyqswgz ) View more | Positive | 21 Sep 2016 | ||
Phase 1/2 | - | - | osrigakzsx(osgacgowvo) = Patient 5 presented hypereosinophilia of undetermined origin after the first injection (mild, grade 2) utjoiqzzpf (mnbmgtpeee ) View more | Positive | 15 May 2015 | ||